MUC13 Cell Surface Mucin Limits Salmonella Typhimurium Infection by Protecting the Mucosal Epithelial Barrier.

Animals Mice Bacterial Infections / genetics Epithelial Cells / metabolism Intestinal Mucosa / pathology Mucins / metabolism Salmonella typhimurium / metabolism
Adhesion Bacterial Invasion Cell Death Epithelial Cell Intestinal Barrier MUC13 Mucin Salmonella

Journal

Cellular and molecular gastroenterology and hepatology
ISSN: 2352-345X
Titre abrégé: Cell Mol Gastroenterol Hepatol
Pays: United States
ID NLM: 101648302

Informations de publication

Date de publication:
2023
Historique:
received: 22 11 2022
revised: 25 08 2023
accepted: 28 08 2023
medline: 27 11 2023
pubmed: 4 9 2023
entrez: 3 9 2023
Statut: ppublish

Résumé

MUC13 cell surface mucin is highly expressed on the mucosal surface throughout the intestine, yet its role against bacterial infection is unknown. We investigated how MUC13 impacts Salmonella typhimurium (S Tm) infection and elucidated its mechanisms of action. Muc13 S Tm-infected Muc13 We show for the first time that MUC13 plays a critical role in antimicrobial defense against pathogenic S Tm at the intestinal mucosal surface by both acting as a releasable decoy limiting bacterial invasion and reducing pathogen-induced cell death. This further implicates the cell surface mucin family in mucosal defense from bacterial infection.

Sections du résumé

BACKGROUND & AIMS
MUC13 cell surface mucin is highly expressed on the mucosal surface throughout the intestine, yet its role against bacterial infection is unknown. We investigated how MUC13 impacts Salmonella typhimurium (S Tm) infection and elucidated its mechanisms of action.
METHODS
Muc13
RESULTS
S Tm-infected Muc13
CONCLUSIONS
We show for the first time that MUC13 plays a critical role in antimicrobial defense against pathogenic S Tm at the intestinal mucosal surface by both acting as a releasable decoy limiting bacterial invasion and reducing pathogen-induced cell death. This further implicates the cell surface mucin family in mucosal defense from bacterial infection.

Identifiants

DOI: 10.1016/j.jcmgh.2023.08.011 PMID: 37660948 PMC: PMC10630632
pubmed: 37660948
pii: S2352-345X(23)00159-5
doi: 10.1016/j.jcmgh.2023.08.011
pmc: PMC10630632
pii:
doi:

Substances chimiques

Mucins 0
Ly64 protein, mouse 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

985-1009

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Michael A McGuckin (MA)

Inflammatory Disease Biology and Therapeutics Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia; Faculty of Medicine Dentistry and Health Sciences, University of Melbourne, Parkville, Victoria, Australia. Electronic address: Michael.mcguckin@unimelb.edu.au.

Julie M Davies (JM)

Inflammatory Bowel Diseases Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia.

Pascal Felgner (P)

CellNanOs, Center for Cellular Nanoanalytics, Osnabrueck, Germany; Division Microbiology, Universitaet Osnabrueck, Osnabrueck, Germany.

Kuan Yau Wong (KY)

Inflammatory Disease Biology and Therapeutics Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia.

Rabina Giri (R)

Inflammatory Bowel Diseases Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia.

Yaowu He (Y)

Cancer Biology Group, Mater Research Institute-University of Queensland, Woolloongabba, Queensland, Australia.

Md Moniruzzaman (M)

Inflammatory Bowel Diseases Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia; School of Pharmacy, The University of Queensland, Woolloongabba, Queensland, Australia.

Thomas Kryza (T)

Cancer Biology Group, Mater Research Institute-University of Queensland, Woolloongabba, Queensland, Australia.

Haressh Sajiir (H)

Inflammatory Disease Biology and Therapeutics Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia.

John D Hooper (JD)

Cancer Biology Group, Mater Research Institute-University of Queensland, Woolloongabba, Queensland, Australia.

Timothy H Florin (TH)

Inflammatory Bowel Diseases Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia.

Jakob Begun (J)

Inflammatory Bowel Diseases Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia.

Abderrahim Oussalah (A)

Department of Molecular Medicine, Division of Biochemistry, Molecular Biology, Nutrition, and Metabolism, University Hospital of Nancy, Nancy, France; University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, Nancy, France; Reference Center for Inborn Errors of Metabolism (ORPHA67872), University Hospital of Nancy, Nancy, France.

Sumaira Z Hasnain (SZ)

Inflammatory Disease Biology and Therapeutics Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia.

Michael Hensel (M)

CellNanOs, Center for Cellular Nanoanalytics, Osnabrueck, Germany; Division Microbiology, Universitaet Osnabrueck, Osnabrueck, Germany.

Yong H Sheng (YH)

Inflammatory Disease Biology and Therapeutics Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia; Laboratory of B-Lymphocytes in Autoimmunity and Malignancies, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. Electronic address: Yong.Sheng@QIMRBerghofer.edu.au.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › MUC13 Cell Surface Mucin Limits Salmonella...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › MUC13 Cell Surface Mucin Limits Salmonella...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › MUC13 Cell Surface Mucin Limits Salmonella...
questionsmedicales.fr › Cellules › Cellules épithéliales › MUC13 Cell Surface Mucin Limits Salmonella...
questionsmedicales.fr › Tissus › Membranes › Muqueuse › Muqueuse intestinale › MUC13 Cell Surface Mucin Limits Salmonella...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Glycoprotéines › Mucoprotéines › Mucines › MUC13 Cell Surface Mucin Limits Salmonella...
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Enterobacteriaceae › Salmonella › Salmonella enterica › Salmonella typhimurium › MUC13 Cell Surface Mucin Limits Salmonella...